Trial Profile
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 08 Jan 2021 Status changed from active, no longer recruiting to completed.
- 03 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 02 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.